CA2443840A1 - Cripto blocking antibodies and uses thereof - Google Patents
Cripto blocking antibodies and uses thereof Download PDFInfo
- Publication number
- CA2443840A1 CA2443840A1 CA002443840A CA2443840A CA2443840A1 CA 2443840 A1 CA2443840 A1 CA 2443840A1 CA 002443840 A CA002443840 A CA 002443840A CA 2443840 A CA2443840 A CA 2443840A CA 2443840 A1 CA2443840 A1 CA 2443840A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- cripto
- group
- epitope
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 title claims abstract 40
- 230000000903 blocking effect Effects 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 19
- 230000004614 tumor growth Effects 0.000 claims abstract 8
- 102100034134 Activin receptor type-1B Human genes 0.000 claims abstract 4
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims abstract 4
- 230000003993 interaction Effects 0.000 claims abstract 4
- 230000011664 signaling Effects 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010061968 Gastric neoplasm Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 7
- 210000000481 breast Anatomy 0.000 claims 7
- 210000001072 colon Anatomy 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 7
- 210000004072 lung Anatomy 0.000 claims 7
- 208000037841 lung tumor Diseases 0.000 claims 7
- 210000001672 ovary Anatomy 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 230000002381 testicular Effects 0.000 claims 7
- 208000025421 tumor of uterus Diseases 0.000 claims 7
- 210000003932 urinary bladder Anatomy 0.000 claims 7
- 206010046766 uterine cancer Diseases 0.000 claims 7
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 7
- 102000012545 EGF-like domains Human genes 0.000 claims 6
- 108050002150 EGF-like domains Proteins 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000025189 neoplasm of testis Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
The invention provides Cripto blocking antibodies, or biologically functiona l fragments thereof, and uses thereof. Antibodies which bind Cripto and modula te Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Crip to and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulat e tumor growth are provided. The invention also provides methods of using thes e antibodies in therapeutic, diagnostic, and research applications.
Claims (61)
1. An antibody that specifically binds to an epitope in the ligand/receptor binding domain of Cripto.
2. The antibody of claim 1 wherein the Cripto is selected from the group consisting of SEQ ID NO: 1 or 2.
3. The antibody of claim 2 wherein the epitope is in an EGF-like domain.
4. The antibody of claim 2 wherein the epitope is in a cys-rich domain.
5. The antibody of claim 2 which is selected from the group consisting of A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A8H3.1, A8H3.2, A19A10.30, A10B2.18, A27F6.1, A40G12.8, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, A19E2.7, B3F6.17, and B6G7.10.
6. The antibody of claim 3 which is selected from the group consisting of A40G12.8, A8H3.1, A27F6.1, B6G7.10, A17G12.1 and A18B3.11.
7. The antibody of claim 4 which is selected from the group consisting of A19A10.30, A8G3.5, A6F8.6 and A6C12.11.
8. An antibody that specifically binds to an epitope comprised in the domain spanning amino acid residues 46-62 of Cripto.
9. The antibody of claim 8 which is A10B2.l8 and B3F6.17.
10. An antibody which binds specifically to an epitope selected from the group of epitopes to which antibodies A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A8H3.1, A8H3.2, A19A10.30, AlOB2.18, A27F6.1, A40G12.8, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, A19E2.7, B3F6.17, and B6G7.10 bind.
11. An antibody which binds specifically to Cripto and is capable of modulating Cripto signaling.
12. The antibody of claim 11 which specifically binds to an epitope in an EGF-like domain of Cripto.
13. The antibody of claim 12 which is selected from A40G12.8, A8H3.1 and A27F6.1.
14. The antibody of claim 11 which specifically binds to an epitope in a cys-rich domain of Cripto.
15. The antibody of claim 14 which is A6C12.11.
16. The antibody of claim 11 which is selected from the group consisting of A40G12.8, A8H3.1, A27F6.1, and A6C12.11.
17. An antibody which binds specifically to Cripto and is capable of modulating tumor growth.
18. The antibody of claim 17 which specifically binds to an epitope in an EGF-like domain of Cripto.
19. The antibody of claim 17 which specifically binds to an epitope in a cys-rich domain of Cripto.
20. The antibody of claim 17 which is selected from the group consisting of A27F6.1, A8G3.5 and B6G7.10.
21. An antibody which binds specifically to Cripto, which is capable of modulating Cripto signaling, and which is capable of modulating tumor growth.
22. The antibody of claim 21 which specifically binds to an epitope in an EGF-like domain of Cripto.
23. The antibody of claim 21 which specifically binds to an epitope in a cys-rich domain of Cripto.
24. The antibody of claim 21 which is A27F6.1.
25. An antibody produced by a hybridoma selected from the group consisting of A6F8.6 (ATCC Accession No. PTA-3318), A8G3.5 (ATCC Accession No. PTA-3317), A8H3.1 (ATCC Accession No. PTA-3315), A10B2.18 (ATCC Accession No.
PTA-3311), A27F6.1 (ATCC Accession No. PTA-3310), A40G12.8 (ATCC Accession No. PTA-3316), A17G12.1 (ATCC Accession No. PTA-3314), A18B3.11 (ATCC
Accession No. PTA-3312), B3F6.17 (ATCC Accession No. PTA-3319), and B6G7.10 (ATCC Accession No. PTA-3313).
PTA-3311), A27F6.1 (ATCC Accession No. PTA-3310), A40G12.8 (ATCC Accession No. PTA-3316), A17G12.1 (ATCC Accession No. PTA-3314), A18B3.11 (ATCC
Accession No. PTA-3312), B3F6.17 (ATCC Accession No. PTA-3319), and B6G7.10 (ATCC Accession No. PTA-3313).
26. An antibody which binds specifically to Cripto and is capable of blocking the interaction between Cripto and ALK4.
27. The antibody of claim 26 which specifically binds to an epitope in an EGF-like domain of Cripto.
28. The antibody of claim 26 which specifically binds to an epitope in a cys-rich domain of Cripto.
29. The antibody of claim 26 which is selected from the group consisting of A8G3.5, A6F8.6 and A6C12.11.
30. An antibody which binds specifically to Cripto, which is capable of blocking the interaction between Cripto and ALK4, and which is capable of modulating tumor growth.
31. The antibody of claim 30 which specifically binds to an epitope in an EGF-like domain of Cripto.
32. The antibody of claim 30 which specifically binds to an epitope in a cys-rich domain of Cripto.
33. The antibody of claim 30 which is A8G3.5.
34. A Cripto antibody capable of internalizing Cripto.
35. The antibody of claim 34 wherein the antibody is conjugated to a chemotherapeutic.
36. The antibody of claim 34 which is selected from A27F6.1 and B3F6.17.
37. A composition for administration to a subject having a tumor that expresses Cripto comprising at least one of the antibodies of any of claims 1-35.
38. The composition according to claim 37, wherein the subject is human.
39. The composition according to claim 37, further comprising a pharmaceutically acceptable excipient.
40. The composition according to claim 37, wherein the antibody is conjugated to a chemotherapeutic.
41. The composition according to claim 37, further comprising a nonconjugated chemotherapeutic.
42. A method of modulating growth of tumor cells in vitro in a sample comprising the step of adding to the sample the composition of claim 37.
43. A method of modulating growth of tumor cells in vivo in a subject comprising the step of administering to the subject an effective amount of the composition of claim 37.
44. The method according to claim 43, wherein the subject is human.
45. A method of treating a subject having a tumor that over-expresses Cripto comprising administering to said subject the composition of claim 37 in an effective amount.
46. A method of treating a patient having a tumor that over-expresses Cripto comprising administering to said patient the composition of claim 39 in an effective amount.
47. A method of treating a patient having a tumor that over-expresses Cripto comprising administering to said patient the composition of claim 40 in an effective amount.
48. A method of treating a patient having a tumor that over-expresses Cripto comprising administering to said patient the composition of claim 41 in an effective amount.
49. The method according to claim 42, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.
50. The method according to claim 43, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.
51. The method according to claim 44, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.
52. The method according to claim 45, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.
53. The method according to claim 46, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.
54. The method according to claim 47, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.
55. The method according to claim 48, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.
56. A method of determining whether a tissue expresses Cripto, comprising the step of analyzing tissue from the subject in an immunoassay using an antibody of any of claims 1-37.
57. A method of determining whether a cell line overexpresses Cripto, comprising the step of analyzing the cell line in an immunoassay using an antibody of any of claims 1-37.
58. The antibody of claim 1 wherein the antibody is monoclonal antibodies.
59. The antibody of claim 1 wherein the antibody is humanized antibodies.
60. The antibody of claim 1 wherein the antibody is human antibodies.
61. A method of treating a subject for a condition associated with undesired cell proliferation, said method comprising administering to said subject the composition of claim 37.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2715570A CA2715570A1 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28678201P | 2001-04-26 | 2001-04-26 | |
US60/286,782 | 2001-04-26 | ||
US29302001P | 2001-05-17 | 2001-05-17 | |
US60/293,020 | 2001-05-17 | ||
US30109101P | 2001-06-26 | 2001-06-26 | |
US60/301,091 | 2001-06-26 | ||
US36700202P | 2002-03-22 | 2002-03-22 | |
US60/367,002 | 2002-03-22 | ||
PCT/US2002/011950 WO2002088170A2 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2715570A Division CA2715570A1 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2443840A1 true CA2443840A1 (en) | 2002-11-07 |
CA2443840C CA2443840C (en) | 2010-10-26 |
Family
ID=27501437
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2443840A Expired - Fee Related CA2443840C (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
CA2715570A Abandoned CA2715570A1 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2715570A Abandoned CA2715570A1 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Country Status (34)
Country | Link |
---|---|
US (6) | US7531174B2 (en) |
EP (3) | EP2316486A3 (en) |
JP (4) | JP4307845B2 (en) |
KR (1) | KR100592357B1 (en) |
CN (1) | CN100352501C (en) |
AR (3) | AR037223A1 (en) |
AT (2) | ATE533508T1 (en) |
BG (1) | BG108363A (en) |
BR (1) | BR0209254A (en) |
CA (2) | CA2443840C (en) |
CL (1) | CL2009002199A1 (en) |
CY (1) | CY1108960T1 (en) |
CZ (1) | CZ20033208A3 (en) |
DE (1) | DE60230868D1 (en) |
DK (1) | DK1390389T3 (en) |
EA (1) | EA007469B1 (en) |
EE (1) | EE200300528A (en) |
ES (1) | ES2321065T3 (en) |
GE (1) | GEP20074091B (en) |
HK (1) | HK1058935A1 (en) |
HU (1) | HUP0501113A3 (en) |
IS (1) | IS2662B (en) |
MX (1) | MXPA03009797A (en) |
MY (2) | MY150237A (en) |
NO (1) | NO20034805L (en) |
NZ (1) | NZ566268A (en) |
PL (1) | PL207087B1 (en) |
PT (1) | PT1390389E (en) |
RS (2) | RS20110024A (en) |
SG (1) | SG157951A1 (en) |
SI (1) | SI1390389T1 (en) |
SK (1) | SK14432003A3 (en) |
TR (1) | TR200301846T2 (en) |
WO (1) | WO2002088170A2 (en) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
JP4307845B2 (en) | 2001-04-26 | 2009-08-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Antibodies that block Cripto and uses thereof |
US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
WO2003083041A2 (en) * | 2002-03-22 | 2003-10-09 | Biogen, Inc. | Cripto-specific antibodies |
CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CA2539116C (en) * | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
CA2543888C (en) | 2003-11-06 | 2016-01-19 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
CN101065151B (en) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
AU2006203889A1 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | CRIPTO binding molecules |
US20100105610A1 (en) * | 2006-07-28 | 2010-04-29 | Children's Memorial Hospital | Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells |
WO2008150530A2 (en) * | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
WO2009131852A1 (en) * | 2008-04-21 | 2009-10-29 | Merck & Co., Inc. | Pancreatic beta-cell mass biomarker |
CN102272157B (en) * | 2008-11-07 | 2015-11-25 | 研究发展基金会 | For suppressing composition and the method for the formation of CRIPTO/GRP78 mixture and signal |
IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US9000130B2 (en) | 2010-06-08 | 2015-04-07 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN103313990B (en) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | Alanyl maytansinol antibody coupling matter |
CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
BR112013027119A8 (en) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | new ligand-drug conjugates (adcs) and their use |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
CA2850371C (en) | 2011-10-14 | 2020-06-30 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
DK2906253T3 (en) | 2012-10-12 | 2018-10-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine anti-PSMA antibody conjugates |
KR101995620B1 (en) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | Pyrrolobenzodiazepine-antibody conjugates |
LT2906251T (en) | 2012-10-12 | 2017-12-11 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
PT2766048E (en) | 2012-10-12 | 2015-02-25 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
ES2660029T3 (en) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Antibody-pyrrolobenzodiazepine conjugates |
CA2887895C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd19 antibody conjugates |
ES2680153T3 (en) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Anti-PSMA-pyrrolobenzodiazepine antibody conjugates |
EP2935273A1 (en) | 2012-12-21 | 2015-10-28 | MedImmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
CN110452242A (en) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and its conjugate |
MX364330B (en) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof. |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
AR096287A1 (en) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | PIRROLOBENZODIACEPINS AND CONJUGATES |
TWI636792B (en) | 2013-08-12 | 2018-10-01 | 建南德克公司 | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
BR112016013258A2 (en) | 2013-12-16 | 2018-01-16 | Genentech Inc | antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
NZ720736A (en) | 2013-12-23 | 2020-08-28 | Bayer Pharma AG | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3388449A3 (en) | 2014-09-12 | 2018-10-24 | F. Hoffmann-La Roche AG | Cysteine engineered antibodies and conjugates |
US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CR20170099A (en) | 2014-09-17 | 2017-07-19 | Genentech Inc | PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
US20180125936A1 (en) * | 2015-04-07 | 2018-05-10 | Paranta Biosciences Limited | Method of treating neoplasias |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN116059390A (en) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | Prodrugs of cytotoxic actives with enzymatically cleavable groups |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7022707B2 (en) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Specific antibody-drug-conjugate (ADC) including KSP inhibitor and anti-CD123 antibody |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
CN110139674B (en) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | Method for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
BR112019012883A2 (en) | 2016-12-21 | 2019-11-26 | Bayer Ag | ligand-drug conjugates (adcs) which have enzymatically cleavable groups |
KR20190099250A (en) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | Prodrugs of Cytotoxic Active Agents with Enzymatically Cleavable Groups |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
EP3544636B1 (en) | 2017-02-08 | 2021-03-31 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
PL3612537T3 (en) | 2017-04-18 | 2022-11-07 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
EP3638373A1 (en) | 2017-06-14 | 2020-04-22 | ADC Therapeutics SA | Dosage regimes for the administration of an anti-cd19 adc |
EP3668874B1 (en) | 2017-08-18 | 2021-12-22 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
AU2018337815A1 (en) | 2017-09-20 | 2020-03-12 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
JP7390315B2 (en) | 2018-06-01 | 2023-12-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Splicing modulator antibody-drug conjugates and methods of use thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
CA3115110A1 (en) | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
JP2022512401A (en) | 2018-12-13 | 2022-02-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Harboxy Diene Splicing Regulatory Antibodies-Drug Conjugates and Their Usage |
KR20210105890A (en) | 2018-12-17 | 2021-08-27 | 레비토프 리미티드 | Twin Immune Cell Engager |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5780029A (en) | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
US6063379A (en) | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
US5981215A (en) * | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US6207153B1 (en) * | 1996-05-22 | 2001-03-27 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
DK2112166T3 (en) | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
CA2368734C (en) | 1999-03-30 | 2005-08-23 | Japan Tobacco Inc. | Method for preparing monoclonal antibody |
CA2370760A1 (en) * | 1999-04-20 | 2000-10-26 | William J. Kokolus | Improved method of identifying and locating immunobiologically-active linear peptides |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
JP2001046066A (en) | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | Antibody against human vegf receptor kdr having new complementary determining region |
JP4028237B2 (en) | 1999-10-29 | 2007-12-26 | ジェネンテック・インコーポレーテッド | Anti-prostate stem cell antigen (PSCA) antibody composition and method of use |
US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
PT1270595E (en) * | 2000-03-03 | 2008-09-16 | Kyowa Hakko Kogyo Kk | Anti ccr4 antibody and its fragment |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
NZ525380A (en) * | 2000-09-18 | 2008-06-30 | Biogen Idec Inc | Non-fucosylated forms of Cripto and their use as tumor blocking agents |
AU2002236871B2 (en) | 2001-01-26 | 2006-09-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Detection and quantification of CRIPTO-1 |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
CN1494553A (en) | 2001-01-29 | 2004-05-05 | IDECҩ�﹫˾ | Modified antibodies and method of use |
AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
JP4307845B2 (en) | 2001-04-26 | 2009-08-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Antibodies that block Cripto and uses thereof |
WO2003083041A2 (en) * | 2002-03-22 | 2003-10-09 | Biogen, Inc. | Cripto-specific antibodies |
US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
EP2174953A1 (en) * | 2001-09-18 | 2010-04-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040014690A1 (en) | 2002-02-13 | 2004-01-22 | Zhenkun Ma | Macrolides with activity against methicillin-resistant staphylococcus aureus |
CA2539116C (en) * | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
AU2006203889A1 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | CRIPTO binding molecules |
CN101479391A (en) | 2006-04-28 | 2009-07-08 | 比奥根艾迪克Ma公司 | Composition and methods for the detection of CRIPTO-3 |
-
2002
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/en not_active Expired - Fee Related
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/en not_active IP Right Cessation
- 2002-04-17 DE DE60230868T patent/DE60230868D1/en not_active Expired - Lifetime
- 2002-04-17 RS RS20110024A patent/RS20110024A/en unknown
- 2002-04-17 EA EA200301158A patent/EA007469B1/en not_active IP Right Cessation
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en active Search and Examination
- 2002-04-17 ES ES02731384T patent/ES2321065T3/en not_active Expired - Lifetime
- 2002-04-17 DK DK02731384T patent/DK1390389T3/en active
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/en unknown
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/en unknown
- 2002-04-17 SI SI200230804T patent/SI1390389T1/en unknown
- 2002-04-17 PL PL373513A patent/PL207087B1/en unknown
- 2002-04-17 RS YU84903A patent/RS51635B/en unknown
- 2002-04-17 EE EEP200300528A patent/EE200300528A/en unknown
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/en not_active Application Discontinuation
- 2002-04-17 AT AT08158456T patent/ATE533508T1/en active
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/en unknown
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 CN CNB028128877A patent/CN100352501C/en not_active Expired - Fee Related
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/en not_active IP Right Cessation
- 2002-04-17 AT AT02731384T patent/ATE420659T1/en active
- 2002-04-17 PT PT02731384T patent/PT1390389E/en unknown
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/en active IP Right Grant
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/en active IP Right Grant
-
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/en unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/en not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/en unknown
-
2004
- 2004-03-11 HK HK04101788.0A patent/HK1058935A1/en not_active IP Right Cessation
-
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/en active Pending
-
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
-
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
-
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/en not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/en unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/en not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/en unknown
-
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/en not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/en not_active Application Discontinuation
-
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2443840A1 (en) | Cripto blocking antibodies and uses thereof | |
JP6463068B2 (en) | Antibodies against MUC16 and methods of use thereof | |
US7420039B2 (en) | Individualized anti-cancer antibodies | |
US7247476B2 (en) | Individualized anti-cancer antibodies | |
JP2004534020A5 (en) | ||
JP2010163438A5 (en) | ||
CN113286817A (en) | DLL3 binding proteins and methods of use | |
KR100909290B1 (en) | Antibodies against cancer | |
RU2004136981A (en) | ANTIBODIES TO IGF-I RECEPTOR | |
WO2013192546A1 (en) | Activatable antibodies having non-binding steric moieties and mehtods of using the same | |
JPH10502544A (en) | Anti-CD30 antibody that prevents proteolytic cleavage and release of membrane-bound CD30 antigen | |
JP2010508847A5 (en) | ||
WO2003055515A1 (en) | Individualized anti-cancer antibodies | |
PT1718737E (en) | Cancerous disease modifying antibodies | |
JP2022106975A (en) | Engineered antibody compounds and conjugates thereof | |
EP1360208B1 (en) | Method for the production of cytotoxic anti-cancer antibodies | |
US10738127B2 (en) | Monoclonal antibodies prevent cell surface protein shedding and block tumor growth | |
CN114025795A (en) | Methods of treating biliary tract cancer using bispecific antigen-binding constructs targeting HER2 | |
CN117750980A (en) | Use of HER 2-targeted antibody-drug conjugates for the treatment of HER 2-underexpressed breast cancer | |
WO2020226612A1 (en) | Anti-carbonic anhydrase ix antibody | |
EP1757305A2 (en) | Individualized anti-cancer antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170418 |